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phonates are widely used and are considered an effective intervention for risk reduc-
tion of postmenopausal fractures. The 100% out-of-pocket purchase of medicines by 
patients is a reality in Brazil. So, a study under patient perspective is an important 
tool to help decision-making. OBJECTIVES: The present study was conducted to 
compare the cost of bisphosphonates used for risk reduction of post-menopause ver-
tebral and non-vertebral fractures under patient perspective in Brazil. METHODS: 
The most important bisphosphonates in the Brazilian market to patients are ibandro-
nate (oral and IV), zolendronate, alendronate and risendronate. There are no head-
to-head clinical trials comparing all the compounds. Studies of ibandronate [Eisman, 
2008] and zolendronate [McClung, 2007] demonstrated their non-inferiority against 
oral bisphosphonates. Therefore, a cost-minimization approach was taken. Drug 
consumer prices were obtained from ofﬁcial public sources [Kairos magazine, May 
2009]. Since the time horizon of this analysis is one-year, no discount rate was utilized. 
Costs are presented in Brazilian Reais (US$1.00^R$2.00 in May 2009). RESULTS: 
Total cost per patient was R$1534.36 for IV ibandronate, R$1685.83 for alendronate, 
R$1941.17 for oral ibandronate, R$1951,26 for zolendronate and R$2354.52 for 
risendronate. CONCLUSIONS: Findings suggest that IV ibandronate is a cost-saving 
therapy with potential of reducing the total treatment cost per patient from 9% up 
to 35%, when compared to alendronate and risendronate respectively, considering 
patient perspective in Brazil.
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OBJECTIVES: To compare the costs of treating osteoarthritis (OA) pain using com-
bination tramadol/paracetamol tablets, Non-Steroidal Anti-Inﬂammatory Agents 
(NSAIDs) alone or NSAIDs plus proton pump inhibitors (PPIs) from the perspective 
of the Spanish National Health System. METHODS: A decision-analytical model was 
constructed to analyse the cost outcomes of the three treatment strategies over 6 
months. A cost-minimisation approach was used, which considered data related to 
resource utilisation, medication costs and costs for the treatment of adverse events. 
Data, derived mainly from the clinical literature, were supplemented by inputs from 
a Delphi panel as well as ofﬁcial price and tariff lists. The base-case analysis considered 
direct medical costs, including those for treating gastrointestinal (GI) and cardiovas-
cular (CV) adverse events. Separate scenario analyses explored costs of NSAID-based 
regimens when renal events attributable to NSAIDs were considered. Univariate sen-
sitivity analysis and scenario analysis considering different levels of adverse events, 
risk and adverse events costs where also carried out. RESULTS: In the base-case 
analysis, costs for 6 months´treatment of OA pain using tramadol/paracetamol were 
a232.86 compared with a274.60 for NSAIDs  PPIs and a133.75 for NSAIDs alone. 
This provided a cost saving of a41.74 per patient over 6 months for tramadol/
paracetamol compared with NSAIDs  PPIs and a cost increase of a99.11 compared 
with NSAIDs alone. When renal adverse events of NSAIDs were considered, trama-
dol/paracetamol was cost saving compared with all NSAID-based regimens (saving 
a140.02 vs NSAIDs alone, a280.86 vs. NSAIDs  PPIs). Sensitivity analysis conﬁrmed 
these results using extreme values of probabilities and unit costs for all options. 
CONCLUSIONS: Tramadol/paracetamol is cost saving compared with NSAIDs  PPIs 
for the treatment of OA pain over a period of 6six months. Tramadol/paracetamol is 
also cost saving compared with treatment with NSAIDs alone if considering renal 
adverse events.
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OBJECTIVES: To evaluate the cost-effectiveness of a treatment sequence including 
tocilizumab 8mg/kg vs the standard treatment sequence (STS) currently used in moder-
ate/severe RA patients following inadequate response to previous DMARD therapy in 
Italy. METHODS: A cost-utility analysis was conducted from a payor’s perspective. 
An individual simulation model was employed to project lifetime cost, and QALYs 
for 10,000 patients. The model compared the STS (etanercept, adalimumab, ritux-
imab, abatacept, and palliative care) with a sequence in which tocilizumab replaces 
etanercept. Patient characteristics (age, HAQ-DI score, sex and weight) were based on 
data from three phase III clinical trials. A mixed treatment comparison was used to 
estimate ACR response rates for each of the treatments in both sequences. Patient data 
from the clinical trials were used to model the relationship between HAQ-DI scores 
and EuroQol (EQ-5D) utilities. Resource utilization, and treatment costs (acquisition, 
administration, and monitoring) were obtained from the literature and the Italian 
formulary. Clinical trial data and available literature provided a basis for ﬁtting 
appropriate distributions to the model parameters in order to perform probabilistic 
sensitivity analysis (PSA). Costs and QALYs were discounted at 3.5%. RESULTS: The 
model estimated that the treatment sequence including tocilizumab produced 0.275 
QALYs more than the standard sequence at additional cost of a984, resulting in an 
ICER of a3586 per QALY. Several sensitivity and scenario analyses showed that the 
model is robust to alternative parameter selections. The results of PSA (1000 samples) 
demonstrated that the ICER for the tocilizumab sequence is always below a threshold 
of a50,000. CONCLUSIONS: In patients who have failed DMARD therapy, the 
model consistently predicts that starting treatment with tocilizumab is cost-effective 
compared to the standard treatment sequence in Italy. The analysis suggests that 
switching between biologic treatments with different modes of action can be a cost-
effective option vs. TNF cycling.
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OBJECTIVES: The purpose of this study was to estimate the cost-utility of a topical 
formulation of diclofenac compared to a standard diclofenac oral preparation in 
patients treated for osteoarthritis of the knee having risk factors for gastrointestinal 
complications (older age or previous GI events). METHODS: For this cost-utility 
analysis, a Markov model was developed based on the model by Maetzel et al.. The 
analysis was performed according to a Minister of Health perspective over a ﬁve-year 
horizon. The model takes into account incidence of gastrointestinal events, incidence 
of complicated gastrointestinal events (perforation and bleeding, mortality), incidence 
of skin related adverse events and use of PPI. Utility estimates associated with each 
health states were taken from published sources. Cost of medications and costs associ-
ated with the management of gastrointestinal events (hospitalisation, emergency visits, 
physician’s visits, endoscopy, etc.) were considered. RESULTS: Cost-utility ratios are 
$39,342 per QALY for patients 65 to 74 years old, $22,019 for those 75 years old 
and more and $24,141 for patients with previous GI events. Base case results were 
robust to various deterministic and probabilistic sensitivity analyses. CONCLU-
SIONS: Topical diclofenac is a cost-effective alternative to oral diclofenac for patients 
having risk factors for GI complications.
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OBJECTIVES: Knee cartilage defects increase the risk of osteoarthritis and prosthesis. 
No standard treatment exists. ChondroCelect® is used in autologous chondrocytes 
implantation (ACI) to treat symptomatic knee cartilage defect. Its efﬁcacy and safety 
was demonstrated in a randomized controlled trial (TIG/ACT/01) vs. the surgical 
procedure microfracture. This study investigated the cost-utility of ChondroCelect® in 
Belgium. METHODS: A decision tree comparing ChondroCelect® to microfracture 
over a 40-year horizon was developed. Key variables were provided by the TIG/
ACT/01 trial (3-year clinical success using the Knee injury and Osteoarthritis Outcome 
Score [KOOS], 1-year structural repair/presence of hyaline [ good quality] cartilage 
based on International Cartilage Repair Society visual item [ICRS II] and utility scores 
by health state derived from the SF-36 questionnaire) and literature (incidence of 
osteoarthritis starting 15 years post-surgery [model assumption], incidence of total 
knee replacement [at 20 years] and prosthesis revision [at 35 years]). A patient chart 
review (n  82 patients) provided follow-up costs by surgery outcome. National tariffs 
were applied to medical resources used (Societal perspective). In accordance to Belgian 
guidelines annual discounting was applied to costs (3%) and effects (1.5%). RESULTS: 
The key TIG/ACT/01 outcomes with Chondrocelect® vs. microfracture were clinical 
success (KOOS) in 83% vs. 61% (p  0.018) and presence of hyaline cartilage (ICRS 
II) in 45% vs. 23% (p  0.010). The incremental cost/QALY gained was a29,397. 
The most sensitive parameters were the proportion of patients with hyaline cartilage 
and the correlation between hyaline cartilage formation and later avoidance of osteo-
arthritis. Probabilistic sensitivity analysis showed robustness of the results, with 60% 
of the simulations falling below a willingness-to-pay of a32,400/QALY (Belgian GDP/
capita, 2008). CONCLUSIONS: A high quality cartilage is expected to translate into 
reduced osteoarthritis development and thus fewer knee replacements. Corresponding 
mid/long term QALYs gained and cost savings made ChondroCelect® use in ACI 
cost-effective in Belgium.
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OBJECTIVES: Japan has been facing an aging society and the burden of illness for 
vertebral compression fracture (VCF) has become a signiﬁcant issue from an economic 
point of view as well as clinical point of view. Reduction of pain and improvement 
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of quality of life with VCF patients after balloon kyphoplasty (BKP) was conﬁrmed 
in a randomised controlled trial (Fracture REduction Evaluation (FREE) trial). Objec-
tive of this study was to examine a cost-effectiveness of BKP in comparison with con-
servative medical management (CMM) for VCF in patients with osteoporosis in Japan. 
METHODS: A disease event simulation model was used to estimate a lifetime cost-
effectiveness of BKP compared to CMM for female VCF patients (70-year-old) with 
osteoporosis in Japan. Payer’s perspective was employed and only medical costs were 
estimated. BKP material price was set at JPY500,000 (a3650, a1  JPY137). Utilities 
were obtained from the FREE trial. Costs and quality-adjusted life years (QALYs) 
occurring beyond 1 year were discounted at 3% per year. Cost-effectiveness was 
evaluated by ICER (Incremental Cost Effectiveness Ratio). RESULTS: BKP was associ-
ated with increased QALYs (0.308 QALYs) compared to CMM. The incremental 
cost-effectiveness ratio for BKP compared to CMM was JPY1,399,947 (a10,219) per 
QALY gained. Probabilistic sensitivity analysis indicated a 76% likelihood that BKP 
would be considered cost-effective in Japan with a willingness to pay of up to JPY 
6 million (a43,796) per QALY gained. CONCLUSIONS: Compared to CMM, BKP 
for Japanese VCF patients was projected to improve QALYs and regarded as 
cost-effective.
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OBJECTIVES: To evaluate the cost-utility of different treatment strategies in the 
treatment of severe RA after the treatment failure with ﬁrst anti-TNF therapy (FATT). 
Before the treatment failure with FATT, patients are assumed to be treated with the 
FIN-RACo combination (methotrexate, sulfasalazine, hydroxychloroquine, and pred-
nisolone). METHODS: The cost-effectiveness of treatment strategies is compared in 
a group of hypothetical Finnish RA patients. After the treatment failure with FATT, 
the patients receive either best supportive care (BSC: intramuscular gold followed by 
cyclosporine and methotrexate) or one of the following treatments before BSC: ritux-
imab, etanercept, adalimumab or inﬂiximab. Further treatments are added to the most 
cost-effective strategy in a stepwise manner. The analysis is performed on an Excel-
based Markov state transition model using the probabilistic approach. The clinical 
outcomes related to treatments are estimated from published clinical trials using 
adjusted indirect comparison. The quality adjusted life-years (QALY) gained are esti-
mated on the basis of Health Utilities Index (HUI-3) and disease severity scores (HAQ). 
The resource use and costs are obtained from the Finnish treatment practice, a pub-
lished study of hospitalisations in RA, Finnish Unit Cost list and Finnish Medicine 
Tariff. RESULTS: The treatment with rituximab dominates adalimumab and etaner-
cept after the failure of FATT as it is more effective and less costly. A QALY gained 
with rituximab or inﬂiximab costs a32,083 or a38,490 compared to BSC, respectively. 
The ICERs are a53,606; a54,722 and a37,169 per QALY gained for adding adalim-
umab, etanercept and inﬂiximab to the rituximab strategy, respectively. According 
to the cost-effectiveness acceptability frontier only the treatments with rituximab or 
rituximab followed by inﬂiximab should be considered after the failure of FATT, if 
a50,000 per QALY gained is used as a willingness-to-pay threshold. CONCLUSIONS: 
Treatment with rituximab is a cost-effective 2nd line biologic treatment strategy in 
RA patients in Finland.
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OBJECTIVES: Poor compliance and failure to persist with osteoporosis medications 
are common, but the clinical and economic consequences have not been well 
described. This study aims to estimate the clinical and economic burden of nonadher-
ence with oral bisphosphonates in osteoporotic patients and to examine the scope for 
adherence-enhancing interventions. METHODS: A validated Markov microsimula-
tion model estimated costs and outcomes (i.e. the number of fractures and the 
quality-adjusted life-year (QALY)) for three adherence scenarios: no treatment, real-
world adherence and full adherence over three years. Simulated patients matched the 
populations where osteoporosis medications are reimbursed. The real-world adher-
ence scenario employed adherence data from a published Belgian observational study 
and adherence was divided into persistence and compliance. The incremental cost per 
QALY gained was estimated comparing the three adherence scenarios. We also 
examined the clinical and economic implications of adherence-enhancing interven-
tions assuming that adherence failure would be reduced by 10%, 20% or 30%. 
RESULTS: The estimated number of fractures prevented and the lifetime QALY 
gained in the real-world adherence scenario represents only 42.0% and 41.9% to 
that obtained under full adherence scenario, respectively. The cost per QALY gained 
of real-world adherence versus no treatment was estimated at a11,175, and full 
adherence was found to be cost-saving compared to real-world adherence. An inter-
vention that decreases adherence failure by 20% was associated with a 28% increase 
in the number of fractures prevented and the costs per QALY gained compared to 
real-world adherence were respectively a29,350 and a46,275 if the intervention costs 
a100 and a150 per year. CONCLUSIONS: This study suggests that more than half 
of the potential beneﬁts from oral bisphosphonates in patients with osteoporosis are 
lost due to poor compliance and failure to persist. Depending on its cost, interven-
tions that improve adherence to therapy have the potential to be an attractive use of 
resources.
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OBJECTIVES: Because little is known about the cost effectiveness of exercise therapy, 
general practitioners lack the knowledge to apply the most cost effective treatment to 
patients with the patellofemoral pain syndrome (PFPS). Therefore, we aimed to deter-
mine the cost effectiveness of exercise therapy (intervention group) compared to ‘usual 
care’ (control group) in adolescents and young adults dealing with PFPS in primary 
care. METHODS: This multicenter prospective cost-utility analysis was conducted at 
38 general practices and 3 sport medical advice centers in The Netherlands for 2007. 
A total of 131 patients between 14 and 40 years of age presenting with symptoms of 
PFPS and no history of previous active treatment were recruited. Direct medical and 
productivity costs were included for the follow up duration of one year. RESULTS: 
The annual direct medical costs per patient were signiﬁcantly higher for the interven-
tion group (a434) compared to the control group (a299), mainly caused by additional 
physiotherapy visits. Productivity costs amounted to a577 (SD2384) and a867 
(SD2192) for the two groups respectively, resulting in annual societal costs per patient 
which were signiﬁcantly lower in the intervention group (a 1,011 versus a1.166). 
Productivity costs due to reduced efﬁciency at paid work were responsible for 47% 
of the total costs in the intervention and 56% and in the control group. Patients in 
the intervention group experienced a slightly, but not signiﬁcantly, higher quality of 
life (0.8722 versus 0.8617). CONCLUSIONS: When only direct medical costs were 
included, average costs per quality adjusted life year (QALY) were a12,754. However, 
with a societal average cost effectiveness ratio of –a14,738 per QALY, exercise therapy 
appears to be cost effective as compared to ‘usual care’. The intervention was domi-
nant in 52% of the cases (positive health effects and cost savings) and inferior in 
14%.
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OBJECTIVES: Herniated discs (HDs) and depression place a signiﬁcant burden on 
employers. Although less prevalent, fractures may also have associated burden. The 
objective of this study was to evaluate the burden of fractures compared to HD and 
depression in terms of short-term disability (STD). METHODS: A descriptive retro-
spective analysis was conducted to assess STD associated with fractures (hip, non-
vertebral composite, vertebral). Medstat/MarketScan’s Health and Productivity 
Management data from 2003–2007 were used. All patients were 45–64 year-old 
employees, stratiﬁed by gender. Fracture-related STD was deﬁned as STD absence 7 
days prior to 14 days after the date of ﬁrst diagnosis of fracture. Cases were matched 
with a control with HD and a control with depression by age, gender, occupation, 
region, insurance type, and years of STD eligibility. RESULTS: HD and depression 
incidence was 30 and 55 per 1000 patient-years, respectively. Fracture incidence 
ranged from 0.6 cases for hip to 7 cases for nonvertebral fractures per 1,000 patient-
years. However, a higher proportion of fracture patients had an STD absence com-
pared to HD and depression controls. The proportion of events with an STD absence 
in women was 16.4% vs. 5.1%, 16.5% vs. 3.5%, and 11.8% vs. 5.4% for hip, non-
vertebral, and vertebral fractures vs. depression, respectively. For men, the rates were 
30.6% vs. 5.1%, 23.6% vs. 5.9%, and 23.7% vs. 6.7%. Comparison to HD controls 
yielded similar results. All p-values were 0.01. Among fracture patients, the mean 
days of STD absence (MDA) ranged from 93 (nonvertebral) to 148 (hip). The MDA 
was signiﬁcantly higher (p  0.05) in women for vertebral (vs. HD controls) and in 
men for hip (vs. both controls), vertebral (vs. depression controls), and non-vertebral 
fractures (vs. depression controls). CONCLUSIONS: Although fracture incidence is 
lower than HDs or depression, fractures produce signiﬁcantly higher STD burden per 
event in 45–64 year-old employees.
PMS62
INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR 
DETERMINANTS
Maurel F1, Bardoulat I1, Camara C2, Schadtler Law L3, Le Pen C4
1IMS Health, Puteaux, France, 2Wyeth Pharmaceuticals France, Paris La Défense, France, 
3Wyeth Pharmaceuticals France, Paris La Défense Cedex, France, 4Dauphine University, Paris, 
France
OBJECTIVES: To determine indirect costs of RA and investigate factors potentially 
associated with higher indirect costs. METHODS: A mail survey was carried out 
among working age Rheumatoid Arthritis (RA) patients members of one RA patients’ 
association in France. Information on demographics, disease parameters, past and 
on-going treatments and employment status was collected. In addition, two validated 
instruments, Health Assessment Questionnaire (HAQ) and the EuroQoL-5 Dimension 
were considered. Annual indirect costs including sick leaves and RA-early retirement 
were valued from the French Health Insurance perspective. Two multiple logistic 
regression models were run to explain respectively the probability of having positive 
